SALT LAKE CITY, Dec. 4, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that it will present SkinTE™ clinical outcomes at the Innovations in Wound Healing Conference held in Key West, FL December 6-9, 2018.
During a presentation entitled, Regeneration of Functional Skin, Stephen Milner, MD, DDS, DSc, FRCSE, FACS and Chief Clinical Officer of PolarityTE, who practiced medicine for more than 20 years and served as former Professor of Plastic and Reconstructive Surgery at the Johns Hopkins University School of Medicine and former Director of Johns Hopkins Burn Center, will discuss SkinTE clinical outcomes data. Dr. Milner will highlight utilization of the autologous SkinTE cell-tissue product in chronic, burn and acute traumatic wounds. The presentation is scheduled during Scientific Session 8 on Sunday, December 9, 2018.
This unique conference is led by a group of experienced educators, scientists and clinicians interested in communicating new approaches to the repair of tissues throughout the human body. The program will focus on the science of tissue repair, the implementation of new findings and the exchange of the latest advances and thinking in the field. Participants, who include clinicians, developers, students and scientists from government, academia and industry, all share an interest in innovative ideas and novel therapies of tissue regeneration and the treatment of chronic wounds. Attendees come from the country's foremost academic institutions and high-volume medical centers and include notable individuals from the wound care field like leaders from the nation's largest provider of advanced wound healing services.
"Medical conferences such as 'Innovation in Wound Healing' allow PolarityTE to share some of its clinical outcomes and help to inform the community about advances in wound care. I am pleased to share with colleagues the favorable results that can be achieved with SkinTE in the regeneration of full-thickness skin replacement. Such meetings provide an opportunity to exchange ideas and experiences as they relate to the newest therapies," said Stephen Milner, MD, Chief Clinical Officer of PolarityTE.
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.
SkinTE is a human cellular and tissue-based product derived from a patient's own skin intended for the repair, reconstruction, and replacement of skin tissue. SkinTE results have shown the regeneration of full-thickness (epidermis, dermis and hypodermis), functionally-polarized skin with all the appendages including hair and glands.
SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products. SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory. SkinTE is marketed as an HCT/P regulated by the FDA solely under Section 361 of the Public Health Service Act and 21 CFR 1271.
Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).
POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, WELCOME TO THE SHIFT, and SKINTE are trademarks or registered trademarks of PolarityTE, Inc.
VP, Investor Relations
LifeSci Advisors, LLC
SOURCE PolarityTE, Inc.